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Abstract 
Arginine  vasopressin  (AVP),  which  is  also  called  antidiuretic  hormone  (ADH),  is  a
neurohormone  synthetized  from  a  pre-pro-hormone  precursor  in  the  supraoptic  and
paraventricular nuclei of the hypothalamus in response to increased plasma osmolality and
decreased blood volume. AVP exerts several effects by binding to three different receptors:
V1aR,  V1bR,  and  V2R.  In  recent  years,  it  has  been  suggested  that  increased  plasma
concentration  of  AVP may play a  causal  role  in  the development  of  type  2 diabetes,  the
metabolic  syndrome,  renal  dysfunction  and cardiovascular  disease  by influencing glucose
homeostasis and lipid metabolism through several possible mechanisms involving V1aR and
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V1bR. V1aR located in the liver is involved in hepatic glycogenolysis and gluconeogenesis.
V1bR, found in the pituitary gland and pancreas, mediates secretion of adrenocorticotrophic
hormone (ACTH),  insulin,  and glucagon.  However,  AVP’s  clinical  use  as  a  biomarker  is
limited due to its short half-life in plasma (16–20 minutes), small size, and poor stability,
which  make  direct  measurement  difficult.  Copeptin,  the  biologically  inactive,  stable,  C-
terminal part of pro-vasopressin, is co-secreted with AVP in equimolar amounts and thus is
considered an adequate and clinically useful surrogate marker of AVP. The aim of this review
is to assess the current state of knowledge about the potential role of copeptin as a novel
biomarker of cardiometabolic syndrome on the basis of recent scientific literature published
up to December 2020 and searches of the PubMed, Google Scholar,  and Web of Science
databases.
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Introduction
Arginine  vasopressin  (AVP),  which  is  also  called  antidiuretic  hormone  (ADH),  is  a
neurohormone  synthesized  from  a  pre-pro-hormone  precursor  in  the  supraoptic  and
paraventricular nuclei of the hypothalamus in response to increased plasma osmolality and
decreased blood volume. It is then transported via axons to the neurohypophysis and released
in  response  to  osmo-  or  baroreceptor  stimuli.  During  the  transport  pre-pro-vasopressin  is
cleaved to vasopressin, neurophysin II, and the C-terminal copeptin [1-4]. AVP exerts several
effects by binding to 3 different receptors: V1aR, V1bR, and V2R (Fig. 1) [4]. One of AVP’s
most important physiological functions is maintaining stable plasma osmolality by promoting
renal water conservation through vasopressin type 2 receptors located in the renal collecting
ducts [3, 4]. 
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Recently,  it  has been pointed out that the AVP system significantly influences glucose
homeostasis and lipid metabolism through several possible mechanisms [1, 5–9]. Firstly, AVP
promotes hepatic glycogenolysis,  gluconeogenesis, and triglyceride production through the
activation of V1aR [1,  3, 4,  7, 9–11].  Secondly,  V1bR, which is mainly expressed in the
adenohypophysis, mediates the release of adreno-corticotrophin hormone (ACTH) and in turn
stimulates  cortisol  secretion  in  response  to  stress  factors.  Under  those  circumstances  the
synergistic effect of both AVP and corticotrophin-releasing hormone (CRH) is over 30 times
greater than that of CRH alone [12, 13]. Interestingly, AVP-stimulated increased pituitary-
adrenal  axis  activity  is  resistant  to  cortisol  negative  feedback  loop,  leading  to
hypercortisolaemia and development of a mild Cushing-like phenotype [14, 15]. Moreover,
the V1bR is also expressed in the Langerhans islets of the pancreas, where it mediates either
insulin or glucagon secretion, depending on the extracellular glucose level [9–11].
In recent years, it has been suggested that increased plasma concentration of AVP may
play a causal role in the development of type 2 diabetes, metabolic syndrome, and chronic
kidney and cardiovascular  diseases  [1,  3,  5,  7,  13–15].  However,  AVP’s  clinical  use as  a
biomarker is limited due to its short half-life in plasma (16–20 minutes), small size, and poor
stability,  which  make  direct  measurement  difficult  [3,  4,  6].  Copeptin,  the  biologically
inactive,  stable,  C-terminal  part  of pro-vasopressin,  is  co-secreted with AVP in equimolar
amounts and is thus considered an adequate and clinically useful surrogate marker of AVP [2,
7, 15–17]. In healthy individuals the copeptin plasma concentration ranges from 1 to 13.8
pmol/L, with an average of 4.2 pmol/L and with a significant difference between women and
men – with lower values in females [2, 4, 6, 16].
The aim of this review is to outline the potential role of copeptin as a novel biomarker of
cardiometabolic syndrome.
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Copeptin and metabolic syndrome
Lately, it has been emphasized that the AVP system is involved in regulating metabolic
homeostasis in humans. High circulating plasma copeptin levels have been associated with
several components of metabolic syndrome, such as abdominal obesity,  insulin resistance,
glucose  intolerance,  hyperinsulinaemia,  hypertension,  and  dyslipidaemia  [14,  15,  18–21].
Several studies have been carried out on a Swedish cohort from the Malmo Diet and Cancer
Study (MDC). The first showed a positive association – independent of other well known risk
factors  –  between  plasma  copeptin  and  components  of  metabolic  syndrome  such  as
hypertension,  abdominal  obesity,  obesity,  c-reactive  protein,  and  the  metabolic  syndrome
itself. Moreover, high plasma copeptin was associated with high fat intake and low physical
activity [22]. However, in a subsequent study on the same population, during a long-term
follow-up of 15.8 years, copeptin independently predicted only abdominal obesity but not the
cluster of the metabolic syndrome [23].
In  a  recent  observational,  population-based  study an  association  between  elevated
plasma copeptin and various features of metabolic syndrome, including haemoglobin (HbA1c),
glucose, triglycerides, high-density lipoprotein (HDL) cholesterol, body mass index (BMI),
and waist circumference, were found [24]. Similarly, in another study, subjects with metabolic
syndrome had plasma copeptin concentration above 5 pmol/L [3, 9]. Vintila et al. showed that
increased  concentrations  of  copeptin  were  associated  with  metabolic  syndrome  and  its
components such as obesity, dyslipidaemia, and insulin resistance in a Romanian population
[25]. A Swiss multicentre,  population-based study investigated the association of copeptin
with insulin resistance and metabolic syndrome. The authors concluded that insulin resistance
was  positively  correlated  with  copeptin  concentrations,  but  only  in  the  eldest  group  of
participants (age 54–69 years) [26]. However, there are limited data concerning the influence
of weight loss on copeptin levels. Interestingly, a study by Aktimur et al. showed that copeptin
4
concentrations decrease after weight loss induced by bariatric surgery [27]. Of note, several
animal and human studies revealed that the AVP system has a significant effect not only on
glycaemia and glucose tolerance but also on hepatic steatosis [28–30]. 
In a  population-based study,  carried out  on South Africans  with mixed ethnicities,
Enhorning et al. demonstrated a significant correlation between elevated copeptin and higher
occurrence  of  non-alcoholic  fatty  liver  disease  (NAFLD).  Furthermore,  copeptin  was
positively correlated with elevated HbA1c, insulin, HOmeostatic Model Assesment – Insulin
Resistance (HOMA-IR), BMI, and waist circumference, and was negatively correlated with
HDL. No significant differences between ethnicities were found [30]. Similar results were
presented  by  Barchetta  et  al.  The  association  between  elevated  plasma  copeptin
concentrations and higher prevalence of metabolic syndrome, visceral obesity, and NAFLD,
confirmed by the liver biopsy, was revealed in this study [29]. 
Copeptin and diabetes mellitus
The  association  between  hyper-secretion  of  AVP  and  copeptin  and  the  risk  of
developing type 2 diabetes has been recently investigated in several studies [11, 13, 25, 31].
Previously, it has been suggested that increased levels of AVP in diabetes mellitus result from
a hyperglycaemia-mediated increase in plasma osmolality and polyuria leading to a relative
reduction in extracellular fluid volume [32]. However, recently, most authors indicate a causal
pathogenic role  for AVP in diabetes  rather than an increase induced by the disease itself,
because in healthy subjects AVP infusion has been reported to cause hyperglycaemia, and
elevated copeptin concentrations are observed many years before the onset of diabetes [5, 33].
Based on data emerging from animal studies, suggesting a pathogenic role of AVP in
glucose  metabolism,  Enhorning  et  al.  carried  out  a  population-based  study to  assess  the
5
association between plasma levels of copeptin and prevalent diabetes, insulin resistance, and
incident diabetes during 12.6 years of follow-up [5]. The results showed that plasma copeptin
levels  were  higher  among  individuals  with  diabetes  compared  to  non-diabetic  subjects.
Moreover, elevated plasma copeptin predicted future development of type 2 diabetes mellitus,
independently  of  glucotoxicity  or  insulin  resistance  at  baseline.  Subjects  who  developed
diabetes mellitus after 12.6 years of follow-up had a median copeptin level 40% higher than
control subjects [3, 5]. Additionally, plasma copeptin concentrations positively correlated with
hyperinsulinaemia.  Another  study,  based  on  the  same  population,  showed  a  positive
correlation between increased copeptin levels at  baseline and the development of incident
type 2 diabetes, abdominal obesity, and microalbuminuria during a long-term follow-up of
15.8  years  [23].  Popovic  et  al.  observed  that  median  copeptin  concentrations  increased
depending on the diabetic status of the subjects, from 6.0 pmol/L (people without diabetes),
through 7.3 pmol/L (prediabetes), to 8.5 pmol/L (type 2 diabetes). A similar correlation was
found between copeptin levels and patients with BMI above or below 35 kg/m2 [34]. Roussel
et al., in a large community-based cohort study, reported an association between high plasma
copeptin concentrations at baseline and reduced insulin sensitivity and increased risk of IFG
or type 2 diabetes during a 9-year follow-up [35]. Interestingly, there are a few studies that
point out the gender-related difference of the correlation between copeptin and risk of type 2
diabetes, with the association stronger in men [33] or in women [8]. 
Copeptin and diabetic complications
In recent years,  several studies have provided strong evidence that increased levels of
copeptin are linked to diabetic macro- and microvascular complications [36–39].
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Copeptin and diabetic microangiopathy
Several  studies  provide  evidence  that  AVP  contributes  to  the  development  and
progression  of  diabetic  nephropathy  and  renal  failure  [23,  32,  37].  Plasma  copeptin
concentrations  have  been  inversely  associated  with  renal  function  estimated  with  the
estimated glomerular filtration rate (eGFR) in subjects with diabetes [32, 37, 40], and they
seemed  stronger  than  the  association  between  well  known risk  factors  such  as  smoking,
HbA1c, and cholesterol [41]. Furthermore, a positive correlation between plasma copeptin and
other markers of renal dysfunction such as blood urea nitrogen (BUN), creatinine, urinary
albumin excretion (UAE), and urine albumin-to-creatinine ratio (UACR) were found [32, 41].
One explanation of the association between copeptin and eGFR, based on results obtained
from animal  studies,  suggests  that  the  underlying  mechanism may be  that  AVP leads  to
hyperfiltration and then to albuminuria and glomerulosclerosis  [41]. These results indicate
that plasma copeptin might be a new prognostic marker for renal function decline in type 2
diabetes patients [40–42].
A few studies have recently focused on the relationship between copeptin and diabetic
retinopathy. The results show that plasma copeptin levels are significantly higher in type 2
diabetes  patients  with  diabetic  retinopathy  when  compared  with  those  without  diabetic
retinopathy [38, 43]. Thus, plasma copeptin could potentially serve as an independent marker
of diabetic retinopathy [44]. 
Copeptin and diabetic macroangiopathy
An  increasing  body  of  data  suggests  that  high  circulating  levels  of  copeptin  are
associated  with  increased  risk  of  heart  and  cardiovascular  disease  as  well  as  premature
mortality, especially in patients with diabetes [2, 13, 14, 19, 30]. There is increasing evidence
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that  copeptin  is  a  biomarker  of  atherosclerosis  in  diabetic  people  [36,  40].  The
pathophysiological  mechanism  underlying  this  phenomenon  is  yet  not  fully  understood.
However, it  is well known that high concentrations of AVP stimulate V1aR preferentially,
inducing  vasoconstriction  and  platelet  aggregation,  thus  potentially  contributing  to  the
cardiovascular  complications  of  diabetes  [45].  Moreover,  V2R  activation  in  endothelium
increases the circulating levels of coagulation factor VIII, von Willebrand factor, and tissue
plasminogen  activator  [36].  In  the  British  Regional  Heart  Study  copeptin  serum  levels
correlated  significantly  with  markers  of  endothelial  dysfunction  and  inflammation
independently of insulin resistance [46].
Enhorning et al. designed a study aimed to assess the role of copeptin as a prognostic
marker  for  diabetic  heart  disease  and  death.  A  strong  relationship,  independent  of
conventional risk factors such as age, sex, LDL, HDL, systolic blood pressure, or smoking,
was found between copeptin and the primary end-point composed of coronary artery disease,
heart failure, and death in diabetic individuals [39]. Interestingly, the association was stronger
among incident diabetic individuals than among prevalent ones. The results suggest that the
AVP system, with its prothrombic and vasoconstrictive properties, may potentiate diabetic
endothelial dysfunction, resulting in an increased risk of cardiac complications of diabetes
[36, 39]. 
Velho et al., in a study on two independent cohorts of people with type 2 diabetes,
confirmed  an  association  between  baseline  plasma  copeptin  levels  and  the  incidence  of
myocardial infarction, coronary revascularisation, congestive heart failure, and cardiovascular
death during a five-year follow-up [40]. Smaradottir et al. analysed copeptin levels in patients
with type 2 diabetes and myocardial infarction at admission, discharge and three months later
and discovered that copeptin serum concentrations at admission were significantly higher than
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at subsequent time points.  Moreover,  copeptin turned out to be a significant predictor for
cardiovascular events at all time points [47]. 
Copeptin and PCOS
Recently,  attention has been drawn to the association between copeptin and insulin
resistance in polycystic ovary syndrome (PCOS) patients. A case-control study on 158 women
with PCOS showed a correlation between copeptin and the risk of increased HOMA-IR ≥ 2.5
[12]. Increased serum copeptin levels have been reported in PCOS patients, especially the
obese ones [48–50]. Moreover, a positive correlation between serum copeptin concentrations
and cardiometabolic parameters such as BMI, WHR, hirsutism score, total testosterone, and
HOMA-IR has been reported [48–50], making copeptin potentially useful for detecting future
cardiovascular risk in PCOS patients. 
The influence of water intake on metabolic profile
The secretion of AVP strongly depends on the level of hydration [28]. People with low
water intake have a considerably higher circulating plasma AVP, lower 24-hour urine volume,
and higher urine osmolality than individuals with higher water intake [51, 52]. Notably, low
water intake and high urine osmolality are linked to an unfavourable metabolic profile at a
population level, indicating that AVP lowering interventions could be beneficial to metabolic
health [14, 24]. Several recent clinical trials and observational studies suggest that increased
water intake is associated with favourable metabolic profile, better glucose control, weight
loss,  and  decreased  cardiovascular  risk  [53–57].  The  water-induced  change  in  copeptin
concentrations was examined by Enhorning et  al.  [1]. The author reported that 1 week of
increased hydration led to a 15% reduction of copeptin on average. Of note, subjects with
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habitual low-water intake and high copeptin presented an even greater reduction in copeptin
of up 40% [1].
In  another  study,  a  significant  reduction  of  both  fasting  copeptin  and  glucose
concentrations was observed in low-drinking individuals after subjecting them to a 6-week
period of increased water intake (1.5 L/day) [24, 55]. This effect can be explained by the fact
that  water  responders  express  a  water-induced  reduction  of  the  diabetogenic  hormone
glucagon [55]. Those findings indicate that water supplementation in persons with habitual
low water intake may improve metabolic profile and reduce diabetes risk.
Conclusions
Several  recent  studies  indicate  that  plasma  copeptin,  the  C-terminal  part  of  the
preprovasopressin,  might  be  used  as  a  potential  novel  risk  factor  for  cardiometabolic
syndrome. Interventions designed to lower AVP plasma concentrations may be beneficial for
the prevention and treatment of various metabolic-related diseases.
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